Company Summary

Diabetic Retinopathy is the leading cause of vision loss in adults worldwide. Opera Therapeutics is developing treatments based on technology from Columbia University that harnesses a natural cellular mechanism to prevent the damage and cell death that are hallmarks of Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO) which account for the majority of vision loss amongst people with diabetes. Unlike currently available anti-angiogenesis therapies which are injected directly into the eye, carry the risk of thromboembolic side effects, and are frequently ineffective, Opera Therapeutics is developing a biologic with a unique mechanism of acting for topical administration as an eye-drop, and aims to bring enhanced relief to patients suffering from diabetic retinopathy without the requirement for regular interocular injections. Opera Therapeutics is additionally exploring the utility of their biologics for treating stroke-induced edema in the brain.

Year Founded:  2017

Key Executives:
• Peter Alff, President

Location:  New York, NY

Company Status:  Private

Year Invested:  2017

Investment Status:  Current

Board Members:
Peter Alff